Nu Skin sales chief Justin Keisel takes medical leave

Nu Skin Enterprises, Inc. (NUS) reported that Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026.

Rhea-AI Filing Summary

Nu Skin Enterprises, Inc. (NUS) reported that Justin Keisel, its Executive Vice President and President of Global Sales, began a medical leave of absence effective August 17, 2026. During his absence, Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark will lead Mr. Keisel’s organization.

The company expresses support for Mr. Keisel as he focuses on his health. No changes to other executive roles or broader strategic initiatives are described in this report.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

medical leave of absence, Executive Vice President, Chief Operating Officer, Chief Legal Officer

4 terms

medical leave of absence other

"began a medical leave of absence"

Executive Vice President financial

"Justin Keisel, the Executive Vice President and President of Global Sales"

An executive vice president is a high-ranking leader within a company who oversees major parts of its operations or strategies. Think of them as senior managers responsible for important areas, similar to a vice principal in a school hierarchy. Their role matters to investors because they help guide the company's success and decision-making at the top level.

Chief Operating Officer financial

"Executive Vice President, Chief Operating Officer and Chief Legal Officer"

A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.

Chief Legal Officer financial

"Executive Vice President, Chief Operating Officer and Chief Legal Officer"

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nu Skin Enterprises (NUS) announce in this Form 8-K?

Nu Skin Enterprises (NUS) announced that Executive Vice President and President of Global Sales Justin Keisel began a medical leave of absence effective August 17, 2026, and that his organization will be led by Executive Vice President, COO and CLO Chayce Clark during his absence.

Which Nu Skin (NUS) executive is taking a medical leave of absence?

The executive taking a medical leave of absence is Justin Keisel, who serves as Executive Vice President and President of Global Sales of Nu Skin Enterprises, Inc.

When did the medical leave for Nu Skin (NUS) executive Justin Keisel become effective?

The medical leave of absence for Nu Skin (NUS) executive Justin Keisel became effective on August 17, 2026, according to the company’s current report.

Who will lead the Global Sales organization at Nu Skin (NUS) during Justin Keisel’s leave?

During Justin Keisel’s medical leave, his organization will be led by Chayce Clark, Nu Skin’s Executive Vice President, Chief Operating Officer and Chief Legal Officer.

Does Nu Skin (NUS) describe any other executive changes in this disclosure?

No. The disclosure only states that Justin Keisel is on medical leave and that Chayce Clark will lead his organization. It does not describe any additional executive changes.

Who signed this Nu Skin (NUS) report and in what capacity?

The report was signed on behalf of Nu Skin Enterprises, Inc. by Chelsea K. Lantz, who is identified as the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:06 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:06 PM EDT Learn about SEC filing dates

false000102156100010215612026-08-172026-08-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 17, 2026

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-12421		87-0565309
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

75 West Center Street

Provo, Utah 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $.001 par value	NUS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective August 17, 2026, Justin Keisel, the Executive Vice President and President of Global Sales of Nu Skin Enterprises, Inc. (the “Company” or “we”), began a medical leave of absence. Chayce Clark, the Company’s Executive Vice President, Chief Operating Officer and Chief Legal Officer, will lead Mr. Keisel’s organization during his time away. We wish Mr. Keisel and his family all the best as he focuses on his health.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

/s/ Chelsea K. Lantz

Chelsea K. Lantz

Chief Financial Officer

Date: August 21, 2026

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB